Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 326 in Hemophilia B Surgery
NCT01507896Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2011
- Primary completion
- May 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of trenonacog alfa in hemophilia B (HB), sponsored by Takeda. Primary endpoints: Intraoperative Hemostatic Efficacy, Actual Intraoperative Blood Loss and 7 more. Started Dec 2011; status: completed.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01507896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01507896.